California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector discovery and product development, has raised $70 million through a Series C financing round. The Series C financing round was led by Viking Global Investors. It also saw participation from new investors such as Amzak Health, Casdin […]
California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has successfully raised $90 million through a Series B financing round. The round was led by Viking Global Investors, with participation from notable investors including ArrowMark Partners, Janus Henderson Investors, The Biotechnology Value Fund, MiraeAsset Financial Group, Pfizer […]
